Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?
Ayhan M, Laçin Ş, Özyükseler DT, Sürmeli H, Doğan A, Turan M, Odabas H, Turan N, Yıldırım ME. Ayhan M, et al. Among authors: yildirim me. J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762. Epub 2021 May 7. J Oncol Pharm Pract. 2021. PMID: 33961521 Free PMC article.
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Yildirim S, Dogan A, Akdag G, Yüksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Alan O, Coban Kokten S, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: yildirim me. Sci Rep. 2024 May 27;14(1):12123. doi: 10.1038/s41598-024-63096-7. Sci Rep. 2024. PMID: 38802494 Free PMC article.
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
Kınıkoğlu O, Odabas H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, Işık D, Başoğlu T, Yıldırım ME, Turan N. Kınıkoğlu O, et al. Among authors: yildirim me. Medicina (Kaunas). 2024 Jun 7;60(6):951. doi: 10.3390/medicina60060951. Medicina (Kaunas). 2024. PMID: 38929568 Free PMC article.
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients.
Yildirim S, Dogan A, Akdag G, Cavdar E, Kinikoglu O, Oksuz S, Yildiz HS, Kucukoz Uzun A, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: yildirim me. Cancers (Basel). 2024 Jul 11;16(14):2512. doi: 10.3390/cancers16142512. Cancers (Basel). 2024. PMID: 39061152 Free PMC article.
Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
Akdag G, Dogan A, Yildirim S, Kinikoglu O, Mokresh ME, Alomari O, Turkoglu E, Isik D, Sürmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: yildirim me. Cureus. 2024 Jun 28;16(6):e63362. doi: 10.7759/cureus.63362. eCollection 2024 Jun. Cureus. 2024. PMID: 39070363 Free PMC article.
Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?
Akdag G, Isik D, Dogan A, Yildirim S, Kinikoglu O, Topal A, Oksuz S, Turkoglu E, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: yildirim me. Medicina (Kaunas). 2024 Aug 22;60(8):1372. doi: 10.3390/medicina60081372. Medicina (Kaunas). 2024. PMID: 39202652 Free PMC article.
93 results